tldrdailynews.com logo

EU Rejections and Setbacks for Duchenne Muscular Dystrophy Gene Therapies

1 min read
Source: statnews.com
EU Rejections and Setbacks for Duchenne Muscular Dystrophy Gene Therapies
Photo: statnews.com
TL;DR

European regulators have decided not to approve the Duchenne muscular dystrophy gene therapy Elevidys, adding to global safety concerns and halting its distribution in Japan and Brazil, with ongoing investigations into safety issues.

Topics:businesshealth#duchenne-muscular-dystrophy#elevidys#europe#gene-therapy#health#regulatory-decision
Share this article
  1. Europe moves to reject embattled Duchenne muscular dystrophy gene therapy  statnews.com
  2. Sarepta-Roche Gene Therapy Fails to Get EU Regulator Approval  Bloomberg
  3. Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU  Roche
  4. CHMP rejects Elevidys in latest setback for Sarepta  Yahoo Finance
  5. Sarepta fails to win EU backing for muscle disorder gene therapy  Reuters

Want the full story? Read the original reporting

Read on statnews.com